Equity research analysts expect Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) reports revenue of $ 155.26 million for the current fiscal quarter, Zacks reports. Five analysts estimated Biohaven Pharmaceutical’s earnings, with the highest sales estimate at $ 170.90 million and the lowest estimate at $ 147.00 million. Biohaven Pharmaceutical reported sales of $ 35.11 million in the same quarter last year, suggesting a positive growth rate of 342.2% year-over-year. The company is expected to announce its next earnings report on Monday, March 7.
On average, analysts expect Biohaven Pharmaceutical to report annual revenue of $ 455.05 million for the current fiscal year, with estimates ranging from $ 419.50 million to $ 591.49 million. of dollars. For the next fiscal year, analysts predict the company will post sales of $ 835.93 million, with estimates ranging from $ 784.40 million to $ 915.20 million. Zacks’ sales calculations are an average based on a survey of research companies that track Biohaven Pharmaceutical.
Biohaven Pharmaceutical (NYSE: BHVN) last released its quarterly earnings data on Monday, November 8. The company reported ($ 2.63) earnings per share (EPS) for the quarter, missing analyst consensus estimates of ($ 2.40) from ($ 0.23). The company posted revenue of $ 135.74 million for the quarter, compared to $ 128.40 million expected by analysts. In the same quarter of the previous year, the company posted ($ 3.27) earnings per share. The company’s revenue increased 668.5% year-on-year.
BHVN has been the subject of several research analyst reports. Mizuho raised his target price on Biohaven Pharmaceutical shares from $ 135.00 to $ 144.00 and gave the stock a “buy” rating in a research report on Thursday, November 18. The UBS group raised its target price on shares of Biohaven Pharmaceutical from $ 150.00 to $ 160.00 in a research report released on Tuesday. Piper Sandler raised her target price on Biohaven Pharmaceutical shares from $ 140.00 to $ 156.00 and rated the stock “overweight” in a research report published on Tuesday, October 5. Morgan Stanley raised its target price on Biohaven Pharmaceutical shares from $ 107.00 to $ 145.00 and gave the stock an “equal weight” rating in a research report published on Tuesday, October 19. Finally, the Goldman Sachs group raised its price target for Biohaven Pharmaceutical shares from $ 151.00 to $ 170.00 and assigned the company a “buy” rating in a research note on Wednesday, October 6. Three equity research analysts rated the stock with a conservation rating and nine gave the stock a buy rating. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $ 147.27.
Separately, director Declan Doogan sold 37,740 shares of the company in a trade on Tuesday, November 16. The shares were sold for an average price of $ 116.65, for a total value of $ 4,402,371.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In addition, director Julia P. Gregory sold 12,000 shares of the company in a transaction on Monday, December 20. The stock was sold at an average price of $ 125, for a total transaction of $ 1,500,000.00. Disclosure of this sale can be found here. During the last quarter, insiders sold 133,099 shares of the company valued at $ 14,807,430. Company insiders own 15.20% of the company’s shares.
Hedge funds and other institutional investors recently changed their holdings of stocks. Marshall Wace LLP purchased a new equity interest in Biohaven Pharmaceutical during the first quarter valued at $ 365,000. Advisor Group Holdings Inc. increased its holdings of shares of Biohaven Pharmaceutical by 6.4% during the second quarter. Advisor Group Holdings Inc. now owns 2,275 shares of the company valued at $ 221,000 after purchasing 137 additional shares in the last quarter. Russell Investments Group Ltd. increased its holdings of shares of Biohaven Pharmaceutical by 87.2% in the second quarter. Russell Investments Group Ltd. now owns 53,892 shares of the company valued at $ 5,231,000 after purchasing an additional 25,103 shares in the last quarter. Envestnet Asset Management Inc. increased its holdings of shares of Biohaven Pharmaceutical by 8.5% during the second quarter. Envestnet Asset Management Inc. now owns 3,763 shares of the company valued at $ 365,000 after purchasing an additional 294 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its holdings of Biohaven Pharmaceutical shares by 17.8% during the second quarter. Teacher Retirement System of Texas now owns 6,594 shares of the company valued at $ 640,000 after purchasing an additional 997 shares in the last quarter. 91.05% of the shares are held by institutional investors.
NYSE: BHVN opened at $ 131.10 on Friday. The company has a market cap of $ 8.59 billion, a PE ratio of -9.58 and a beta of 1.03. Biohaven Pharmaceutical has a twelve month low of $ 62.57 and a twelve month high of $ 151.51. The company’s 50-day moving average is $ 123.17 and its two-hundred-day moving average is $ 124.44.
Profile of the pharmaceutical company Biohaven
Biohaven Pharmaceutical Holding Co Ltd. is a clinical-stage biopharmaceutical company dedicated to the research and development of late-stage product candidates targeting neurological diseases, including rare diseases. It focuses on a pipeline of product candidates that represent mechanistic platforms, peptide receptor antagonists linked to the calcitonin gene, and glutamate modulators.
Further reading: What is the period of silence?
Get a Free Copy of Zacks’ Research Report on Biohaven Pharmaceutical (BHVN)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in Biohaven Pharmaceutical right now?
Before you consider Biohaven Pharmaceutical, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of … and Biohaven Pharmaceutical was not on the list.
Although Biohaven Pharmaceutical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here